Physician profile
Jean You
NPI 1184660029
$6,418.27
in general payments reported to CMS, 2019-2025
24 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,699 · 2020: $427 · 2021: $1,200 · 2022: $1,000 · 2023: $1,152 · 2024: $582 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,099.00 | 2019 | |
| Abbvie INC. | $1,086.79 | 2021-2025 | Ubrelvy, Qulipta |
| Collegium Pharmaceutical, INC. | $895.99 | 2019-2025 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $872.79 | 2019-2025 | Relistor |
| Biodelivery Sciences International, INC. | $508.53 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $483.63 | 2020-2021 | |
| Nusmile, LTD. | $268.27 | 2023 | Sleeperone |
| Biohaven Pharmaceutical Holding Company LTD. | $247.05 | 2022 | |
| Lilly USA, LLC | $247.04 | 2019-2023 | Emgality |
| Pfizer INC. | $199.95 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $122.17 | 2019-2021 | |
| Amgen INC. | $73.63 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $41.44 | 2021-2022 | |
| Eisai INC. | $41.43 | 2021 | |
| Redhill Biopharma INC. | $35.82 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $30.64 | 2019 | |
| Ibsa Pharma INC. | $29.39 | 2020 | |
| Novartis Pharmaceuticals Corporation | $25.68 | 2019 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Indivior INC. | $20.23 | 2021 | |
| Axsome Therapeutics, INC. | $19.09 | 2023 | Sunosi |
| Grt US Holding, INC. | $16.95 | 2020 | |
| Allergan, INC. | $16.27 | 2020 | |
| Shire North American Group INC | $15.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean You listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.